论文部分内容阅读
【目的】探讨瑞舒伐他汀联合叶酸对高血压患者血清同型半胱氨酸(Hcy)、胱抑素C(Cys C)、高敏C反应蛋白(hs-CRP)水平的影响。【方法】选择180例原发性高血压患者,按随机数字表法分为对照组(A组)、瑞舒伐他汀钙组(C组)及瑞舒伐他汀钙联合叶酸片组(C组),每组各60例。A组给予降压药物治疗,对伴有冠心病患者配合口服阿司匹林、硫酸氢氯吡格雷、硝酸酯类药物。B组在对照组用药基础上口服瑞舒伐他汀钙10 mg,每晚1次。C 组在 B 组基础上口服叶酸片5 mg,3次/日,共治疗24周。分别于治疗前,治疗后第4周、第12周及第24周后测定晨起空腹静脉血血清 Hcy、Cys C、hs-CRP 水平,比较三组治疗前、治疗后上述检测指标的变化。【结果】治疗前三组患者血清 Hcy、Cys C、hs-CRP水平对比无明显差异(P>0.05)；治疗第12周时B组、C组上述指标较治疗前下降,差异具有统计学意义(P 0.05),At twelfth week after treatment,the index of group B and group C decreased compared with those before treatment,the difference was statistically significant (P <0.05);At 24th week after treatment,the above parameters of group B and group C dropped further compared with those of 12th week ,and group C de-creased more obviously than group B,the above differences were statistically significant (P 0.05).[Conclusion]Ro-suvastatin can reduce the level of serum homocysteine,Cy-statin C and high sensitive Creactive protein in patients with hyper-tension,the effect is more obvious when it is combined with folic acid,and it can be used as a clinical adj uvant therapy to pre-vent hypertension-related target organ damage.